Background Our previous study in patients with cerebellar ataxias of different causes
showed significant benefit of riluzole after 8 weeks. We aimed to confirm these results in …

Background Riluzole has been reported to be beneficial in patients with cerebellar ataxia;
however, effectiveness in individual subtypes of disease is unclear due to heterogeneity in …

Background: The pleiotropic effects of riluzole may antagonize common mechanisms
underlying chronic cerebellar ataxia, a debilitating and untreatable consequence of various …

Objective To systematically review evidence regarding ataxia treatment. Methods A
comprehensive systematic review was performed according to American Academy of …

Objective We conducted a randomized double‐blind trial of riluzole in Huntington's disease
to investigate the efficacy of this antiexcitotoxic drug in slowing disease progression …

In an open label study, we administered riluzole (50 mg twice a day) to nine patients with
genetically confirmed Huntington's disease (HD)(clinical stages 1–3; mean age 46.4 (SD …

Riluzole - The Lancet Skip to Main Content Advertisement The Lancet Journal Submit Article
Log in Register Log in Submit Article Log in Subscribe Skip menu This journal Read Online first …

Background Severe spinal muscular atrophy (SMA)(Werdnig-Hoffmann disease, acute SMA,
and SMA I) is a disease of the motor neuron characterized by onset before 6 months of age …

Dominantly inherited spinocerebellar ataxias (SCAs) are associated with phenotypes that
range from pure cerebellar to multisystemic. The list of implicated genes has lengthened in …

Background: Riluzole retards striatal glutamate release and pathologic consequences in
neurotoxic animal models of Huntington's disease (HD). Objective: To determine the dosage …